CAS · 1208319-27-0
Product Overview
Oclacitinib Maleate is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance | Off-white to white powder |
|---|---|
| Purity | 99% min |
| Assay | 98.0%~102.0% |
| Identification | IR: Sample spectrum must match standard spectrum HPLC: Retention time of major peak in assay preparation corresponds to standard preparation |
| Solubility | Soluble in DMSO, insoluble in ethyl acetate |
| Melting Point | 128~130 °C |
| pH Value | 4.2-5.8 |
| Water (K.F.) | 5.0% max |
| Loss on Drying | 5.0% max |
| Residue on Ignition | 0.2% max |
| Residual Solvents | Methanol: 3000 ppm max DMF: 860 ppm max Acetonitrile: 390 ppm max n-Butanol: 3000 ppm max Tetrahydrofuran: 700 ppm max |
| Related Substances | Max single impurity: 0.2% max Total impurities: 1.0% max |
Applications
Oclacitinib Maleate (CAS 1208319-27-0) is a pharmaceutical compound primarily used in veterinary medicine for the management of pruritus (itching) associated with allergic dermatitis in dogs. It acts as a selective Janus kinase (JAK) inhibitor, modulating the immune response and reducing inflammation caused by allergic reactions. Oclacitinib Maleate is formulated as an oral tablet for convenient administration in pets and is often used to treat conditions such as atopic dermatitis, flea allergy dermatitis, and other allergic skin disorders. Additionally, it is utilized in veterinary research for studying JAK-STAT signaling pathways and the development of new anti-inflammatory therapies.
Benefits
The benefits of Oclacitinib Maleate arise from its targeted mechanism of action and rapid onset of effect. By selectively inhibiting JAK1 and JAK3, it effectively reduces pro-inflammatory cytokine signaling, providing relief from itching and inflammation without broadly suppressing the immune system. This targeted activity minimizes side effects compared to conventional corticosteroids or systemic immunosuppressants. It has good oral bioavailability, allowing convenient dosing for pets, and its efficacy and safety profile have been well-established in veterinary studies. Its selective action also makes it a useful tool for research into immune-mediated inflammatory pathways.
Conclusion
Oclacitinib Maleate is a targeted veterinary pharmaceutical used to manage allergic dermatitis and pruritus in dogs. Its selective JAK inhibition offers rapid relief from itching and inflammation while minimizing systemic immunosuppression. By combining efficacy, safety, and convenience, Oclacitinib Maleate continues to be an important therapeutic option in veterinary medicine and a valuable tool in immunological research.
Previous
Next